The National Trial Lawyers
BBB
Million Dollar Advocates Forum
10 Best
Asbestos Mesothelioma Trial Lawyers - Top 10
Best Attorneys of America
Veteran Approved
Americas Top 100
Lawyers of Distinction
The American Association For Justice
Best Law Firms Of America
Top American Lawyers

The Food and Drug Administration (FDA) recently announced that it will host a public forum discussing the methods used to test for asbestos fibers in talc-based products, as well as the terminology and criteria that can be used to measure the carcinogen in consumer products. During that forum, the FDA will discuss preliminary recommendations from the Interagency Working Group on Asbestos in Consumer Products (IWGAC)—an interagency working group formed in 2018 to support the development of standardized testing methods for asbestos and other harmful particles.

The purpose of the IWGAC is to address the terminology and definitions of asbestos, recommend improvements for measuring asbestos in talc-based products, and recommend testing standards to test these products. The FDA forum comes two-years after the agency first began investigating reports of asbestos in talcum powder products, during which time it tested 50 such products and confirmed the presence of asbestos in some. One of those examinations in October 2019 revealed the presence of asbestos fibers in a lot of Johnson & Johnson’s Baby Powder, which caused the company to voluntarily recall 33,000 bottles of the iconic product.

Specifically, the IWGAC recommends adopting the term elongate mineral particles (EMP) to be “any mineral particle with a minimum aspect ratio of 3:1,” as to resolve ambiguity and disagreement of asbestos vs non-asbestos identification. Testing laboratories report all EMP having a length of over 500 nm and that testing methods specify reportable EMP identified as certain types of asbestos.

Johnson & Johnson CEO Alex Gorsky recently appeared in a New Brunswick, New Jersey courtroom to testify in a talcum powder asbestos cancer lawsuit brought by four plaintiffs who claim they developed a serious form of cancer from years of using one of the company’s most iconic products. The talcum powder lawsuit alleges that the plaintiffs developed mesothelioma as a result of asbestos exposure from using Johnson & Johnson products like Baby Powder and Shower to Shower while the pharmaceutical and cosmetics giant knew about the risk posed to consumers but chose not to provide any safety warnings on the products.

During his testimony, Gorsky indicated that he relied on company experts when he announced on national television that Johnson & Johnson’s Baby Powder does not contain asbestos and was safe for consumers to use. Despite Gorsky claiming that he did not have firsthand knowledge of the science behind Baby Powder risks, revelations have surfaced in recent months that the company knew for decades about possible risks and that the company still chose to market its products to vulnerable and marginalized communities.

Furthermore, Johnson & Johnson was forced to issue a recall of 33,000 bottles of Baby Powder after independent testing conducted on behalf of the Food and Drug Administration (FDA) discovered the presence of asbestos fibers in the product lot. Those tests have since spurred Congressional oversight committees to call for standardized testing methods and terminology to dispel ambiguity about how results are interpreted and ensure the public at large is protected from products containing deadly asbestos.

Johnson & Johnson’s long time talc supplier is reportedly shopping the sale of its North American talc operations after filing for bankruptcy under the weight of thousands of asbestos cancer lawsuits in which the company was enjoined with the pharmaceutical and cosmetics giant. Those lawsuits, which thus far have produced billions in plaintiffs verdicts, claim that Johnson & Johnson and Imerys produced and marketed talc-based products like Baby Powder and Shower to Shower which contained deadly asbestos fibers and caused the victims’ debilitating and often fatal health conditions.

Among the assets up for supposed sale, Imerys is reported to consider selling strategic alternatives that could include the sale of business in North America as a whole. In February 2019, Imerys filed for Chapter 11 bankruptcy protection, citing that the company was facing more than 14,000 lawsuits in the United States at the time. Reports stress that deliberations are still at an early stage and that no final decisions have been reached as of yet.

The reports are significant in that the proceeds from the sale of Imerys’ North American talc operations could be used to fund settlements of talcum powder cancer lawsuits, through some form of a trust. To do so, Imerys would ultimately need to negotiate with creditors, which would include insurers and those parties involved in asbestos cancer lawsuits.

A recent study conducted by an international team of pathologists has reportedly identified a new protein which is often found in the tumor cells of patients diagnosed with pleural mesothelioma, a rare and deadly form of lung cancer which commonly affects the thin lining of tissue surrounding the lungs. With the discovery, researchers hope that doctors can make a more accurate prognosis for their patients and craft more effective and targeted treatment options to help these individuals live longer, more comfortable lives.

Published in The Journal of Pathology, the study found that the presence of protein CD70 correlates with a worse prognosis in patients with malignant pleural mesothelioma through immune evasion and enhanced invasiveness. The study was led by researchers at Aichi Medical University School of Medicine in Nagakute, Japan, with contributions from doctors based in the U.S., Poland, and Germany.

In the paper, the authors determined that about 20% of the mesothelioma tumor cells examined showed high levels of the CD70 protein, which resulted in a median survival of only six and a half months compared to a survival rate of a year and a half for patients without the over expression of the protein. Researchers believe these findings may explain the significant differences in survival periods between patients with the disease. The same protein has been studied in other serious forms of cancer, including certain types of kidney cancers and brain cancers.

A group of Wisconsin prison inmates recently filed a lawsuit over allegations the plaintiffs are suffering asbestos exposure almost daily due to the facility and state’s negligent management of the institution. According to the federal asbestos lawsuit, 10 inmates at the Prairie du Chien Correctional Institution say the prison is exposing inmates and workers to dangerous levels of black mold, asbestos, and lead-contaminated water.

Filed in U.S. District Court for the Western District of Wisconsin, the asbestos lawsuit claims the prisoner-plaintiffs suffered continuous exposure to asbestos and asbestos-related materials such as lead, lead filings, radium, and rust particles in the prison’s water supply. The lawsuit further claims that the plaintiffs suffered arbitrary denial of access to sanitary cleaning supplies to prevent the spread of disease and bacteria.

The suit seeks about $5 million in damages, as well as an emergency investigation and testing of all buildings at the prison, and evacuation of all inmates and staff from the facility. The latter demand for emergency transfers to minimum-security correctional facilities comes in the form of a preliminary injunction and restraining order filed by the inmates. It is unclear if the group has outside legal counsel in the asbestos cancer lawsuit.

The House of Representatives Committee on Oversight and Reform recently held a hearing examining health risks related to the use of talcum powder products containing asbestos, as well as the detection methods used to keep the public safe. The hearing comes on the heels of news that the Food and Drug Administration (FDA) announced had detected asbestos in one lot of pharmaceutical and cosmetics giant Johnson & Johnson’s Baby Powder and that the company would voluntarily recall 33,000 bottles of the product.

Johnson & Johnson currently faces an estimated 15,000 talcum powder asbestos cancer lawsuits across the country brought by plaintiffs claiming their serious medical conditions, including various forms of cancer, were caused by decades of using Johnson & Johnson’s Baby Powder. Many of those lawsuits allege the plaintiffs developed mesothelioma, a rare and deadly form of cancer directly linked with exposure to microscopic asbestos fibers.

While talc itself does not contain asbestos, the two are both naturally occurring minerals which can often be found side by side one another, creating the possibility of cross contamination if precautions are not taken to protect innocent consumers. Despite federal laws requiring talc products to be asbestos-free, strong evidence exists that Johnson & Johnson continued to produce talc-based products that tested positive for asbestos.

When patients are diagnosed with a debilitating disease such as cancer, their focus often immediately shifts towards whether or not they will require surgery to treat the disease and what, if any, are the least invasive and most effective treatment options. Some forms of cancer can be treated without surgery, using radiation or chemotherapy, if caught in the early stages, while others leave patients with limited treatment options that may leave surgery as the only course of action.

A recent European study compared surgical treatments in patients diagnosed with malignant pleural mesothelioma, a rare and deadly form of cancer affecting the thin lining of tissue surrounding the lungs. The researchers compared data of two types of treatments performed from 1999 through 2018, pleurectomy/decortication (P/D) and extrapleural pneumonectomy (EPP) to see if patients fared better with one treatment over the other in terms of survival.

Mesothelioma has a particularly long latency period, which is the time between exposure to a carcinogen and when a diagnosis is actually made. The disease’s latency period can be anywhere from 20 years to 50 years, which can leave patients with especially limited treatment options and make surgery the only treatment available to prolong the individual’s lifespan.

A federal judge in San Francisco recently allowed a lawsuit to continue against the Environmental Protection Agency (EPA) alleging the agency fails to properly track how much deadly asbestos is imported, manufactured, and otherwise used in products in the United States. Several advocacy groups filed the asbestos lawsuit against the EPA in February 2019, challenging the agencies decision to allow certain exemptions to reporting rules for asbestos products, and the agency’s decision to deny a petition to impose stricter reporting requirements on companies dealing in asbestos.

“EPA has greatly overstated its knowledge of asbestos use and exposure in the United States,” the advocacy groups, now plaintiffs, wrote in a letter to the EPA back in January 2019 in which they urged the agency to reconsider its decision. “This decision gives us the green light to press ahead with our suit to hold EPA accountable for refusing to require simple and straightforward reporting by the asbestos industry,” said Linda Reinstein, president of the Asbestos Disease Awareness Organization, one of the plaintiffs involved in the lawsuit against the EPA.

Other plaintiffs in the lawsuit include the American Public Health Association, the Center for Environmental Health, the Environmental Working Group, the Environmental Health Strategy Center, and Safer Chemicals Healthy Families. A spokesperson for the Environmental Working Group released a statement saying “EPA Administrator Andrew Wheeler’s efforts to keep the public in the dark about where and how asbestos is being used in this country is antithetical to what the American people should expect from the head of the EPA.”

A New Jersey Superior Court judge recently denied a motion by the defendant in a talcum powder asbestos cancer lawsuit which sought to set aide a multimillion dollar verdict handed down by a state jury to a group of plaintiffs who claimed they developed serious forms of cancer due to asbestos fibers in talc-based products produced by the defendant. That lawsuit claimed pharmaceutical and cosmetics giant Johnson & Johnson knowingly sold asbestos-contaminated talcum powder products for years, without any warnings to consumers about the known risks of asbestos exposure.

In September 2019, a Middlesex County, New Jersey jury handed down a $37.3 million verdict to four plaintiffs who claimed they developed mesothelioma cancer as a result of using talc-based products, such as Baby Powder and Shower to Shower, produced by Johnson & Johnson. That trial took place in the city of Brunswick, New Jersey, where Johnson & Johnson’s corporate headquarters is located. The company faces thousands of other such lawsuits in state and federal courts across the country.

Johnson & Johnson’s post-trial motion, which the judge recently denied, had asked the judge to set aside the trial court’s verdict on a multitude of legal grounds. However, that motion was denied by the judge on the grounds that the proceedings in the case had not yet concluded, as the jury’s $37.3 million award only included damages for lost wages, medical bills, other monetary damages, and pain and suffering. The case is set to enter a new phase relatively soon, as the jury will decide what, if any, punitive damages Johnson & Johnson will be required to pay the victims.

A recent report by Reuters details troubling links between the Food and Drug Administration (FDA) and pharmaceutical and cosmetics giant Johnson & Johnson concerning efforts by safety advocates to conduct testing and provide warning labels to consumers about the potential risks of asbestos contamination in talcum powder products. The investigation details how, over decades, the FDA often relied upon testing or otherwise deferred to individuals linked to Johnson & Johnson when making determinations about the safety of the company’s talc-based products.

The special report shows that since the 1970s, federal regulators have deferred to Johnson & Johnson when independent scientists and researchers brought up concerns that talcum powder products may be contaminated with carcinogenic asbestos. When a line of cosmetics products tested positive for asbestos back in March 2019, the FDA noted “We are dependent on manufacturers to take steps to ensure the safety of their products.” Most recently, Johnson & Johnson conducted a voluntary recall of its iconic Baby Powder after the FDA found that the product tested positive for asbestos.

In chronicling the FDA’s deference to Johnson & Johnson, the report shows that federal regulators were concerned about asbestos fibers in talcum powder as far back as the 1970s, but quickly ended inquiries after assurances from companies using talc that their products were safe. Eventually, the role of monitoring and testing talc-based products fell to the Cosmetic Toiletry and Fragrance Association after convincing the FDA that manufacturers were best suited to conduct oversight.

Contact Information